↓ Skip to main content

Dove Medical Press

Article Metrics

Update on the use of rituximab for intractable rheumatoid arthritis

Overview of attention for article published in Open Access Rheumatology : Research and Reviews , July 2009
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#46 of 137)
  • Above-average Attention Score compared to outputs of the same age (57th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
11 Mendeley
Title
Update on the use of rituximab for intractable rheumatoid arthritis
Published in
Open Access Rheumatology : Research and Reviews , July 2009
DOI 10.2147/oarrr.s4968
Pubmed ID
Authors

John Looney

Abstract

It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an inadequate response to anti-TNF therapies. Since approval rituximab has become a part of standard treatment, and additional data have become available on long-term efficacy and safety both from clinical trials and from post-marketing surveillance. In open long-term follow-up from clinical trials, patients treated with multiple courses of rituximab continued to respond in terms of signs and symptoms, and damage assessed radiographically was significantly inhibited. Moreover, the rate of serious infectious events was not increased as the number of courses increased. However, because of case reports of progressive multifocal leukoencephalopathy in patients treated with rituximab for non-malignant conditions, a black box warning has been added. Studies on the immunologic correlates of response to rituximab treatment including B cell subsets in peripheral blood and synovial biopsies are providing clues into how rituximab works for autoimmune disease. However, at this time we are not able to explain why some patients do not respond and cannot predict who will respond. Future challenges for the further development of rituximab for intractable RA will be discussed.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 27%
Student > Doctoral Student 2 18%
Student > Postgraduate 1 9%
Student > Master 1 9%
Unknown 4 36%
Readers by discipline Count As %
Medicine and Dentistry 5 45%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Unknown 5 45%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2020.
All research outputs
#6,052,635
of 18,679,853 outputs
Outputs from Open Access Rheumatology : Research and Reviews
#46
of 137 outputs
Outputs of similar age
#112,710
of 286,988 outputs
Outputs of similar age from Open Access Rheumatology : Research and Reviews
#2
of 2 outputs
Altmetric has tracked 18,679,853 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 137 research outputs from this source. They receive a mean Attention Score of 3.9. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,988 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.